✦ LIBER ✦

Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with Ribavirin, mycophenolate motelil (CellCept®), amantadine, or amantadine plus ribavirin in patients that relapsed on rebetronTM therapy: A preliminary report of a randomized, multicenter efficacy and safety study

✍ Scribed by Herrine, Steven K.; Brown, Robert; Esposito, Stephen; Lok, Anna; Galati, Joseph S.; Bernstein, David E.; Campagna, Jennifer; Pappas, Stephen C.

Book ID: 124120969
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 169 KB
Volume: 120
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(08)81905-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pegylated (40 kDa) interferon alfa-2a (P

Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin, mycophenolate mofetil (CellCept®), amantadine, or amantadine plus ribavirin in patients that did not respond to rebetronTM therapy: A preliminary report of a randomized, multicenter study

✍ Afdhal, Nezam; Flamm, Steven; Imperial, Joanne; Malet, Peter F.; Tong, Myron; Ca 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 157 KB

Pegylated (40 KDA) interferon alfa-2a (P

Pegylated (40 KDA) interferon alfa-2a (PEGASYS®) in new combination therapies: a report of a randomized, multicenter efficacy and safety study

✍ A.M. Di Bisceglie; D.E. Bernstein; V.R. Rustgi; N. Gitlin; L.J. Jeffers; D. Simo 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Pegylated (40kDa) interferon alfa-2a (PE

Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study

✍ Michael W. Fried; Mitchell L. Shiffman; Rejender K. Reddy; Coleman Smith; George 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 196 KB

A 3-ARM randomized study evaluating the

A 3-ARM randomized study evaluating the efficacy of triple therapy of pegylated or recombinant interferon alpha-2a 3 MU both combined with ribavirin and amantadine versus dual therapy of recombinant interferon alpha-2a plus ribavirin in naive patients with chronic HCV hepatitis

✍ Alessandra Mangia; Giovanni Ricci; Nicola Minerva; Marcello Persico; Vito Carret 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 100 KB

Efficacy, quality of life, safety, and t

Efficacy, quality of life, safety, and tolerability in patients with chronic hepatitis C treated with PEG (40 kDa) IFN α-2a (PEGASYS®) or standard interferon Alfa-2b/ribavirin (REBETRON™) combination therapy

✍ Kenneth D. Rothstein; Robert P. Perrillo; Joanne Imperial; Imtiaz Alam; Melissa 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 366 KB

Analyses of 40 kDa peginterferon alfa-2A

Analyses of 40 kDa peginterferon alfa-2A (Pegasys®) in combination with ribavirin, mycophenolate mofetil, amantadine, or amantadine plus ribavirin in patients that relapsed or did not respond to rebetron™ therapy: a report of two randomized, multicenter, efficacy and safety studies: Nezam Afdhal, Beth Israel Deaconess Medical Ctr, Boston, MA; Steven Flamm, Northwestern Memorial Hospital, Chicago, IL; Joanne C Imperial, Stanford University School of Medicine, Palo Alto, CA; Peter F Malet, University of Texas Southwestern Medical Center, Dallas, TX; Myron Tong, Hungtington Hospital Liver Center, Pasadena, CA; Steven K Herrine, Thomas Jefferson University Hospital, Philadelphia, PA; Robert Brown Jr., Columbia Presbyterian Medical Center, New York, NY; Stephen Esposito, Hepatobiliary Associates of New York, Bayside, NY; David E Bernstein, North Shore University Hospital, Manhasset, NY; Jennifer L Campagna, Roche Laboratories Inc, Nutley, NJ

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB